Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Pre-Solicitation opportunity was posted on December 8, 2008. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Nasal Spray Influenza Vaccine

Closed
SPM2DP-09-R-0002Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.
Mrpbs Minneapolis Mn

POSTED

19 days ago

DEADLINE

in 21 days

General Info

Agency

N/A

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Not specified

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

Presolicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A

Full Description

Show more
The Defense Supply Center Philadelphia is soliciting proposals for the supply of Nasal Spray Influenza Virus Vaccine for the 2009/2010 flu season. Shall be a live, trivalent nasally administered vaccine intended for active immunization for the prevention of influenza. Each 0.2 ml dose shall be formulated to contain 10 median tissue culture infectious doses of live attenuated influenza virus reassortants of the strains recommended by the U.S. Public Health Service (USPHS) for the 2009/2010 season. Shall be indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children ages 2 -17 years of age and healthy adults ages 18-49 years of age. Shall be suitable for nasal administration only. Shall be supplied in a commercially available nasal syringe unit considered acceptable to the FDA. This acquisition is authorized under 10 USC 2304 (c) 1, Only One Responsible Source. The one responsible source being solicited is MedImmune, Inc. Approximately 164,520 PG (10 dose per package) are included in this requirement. (Quantities may increase or decrease substantially pending receipt of Service requirements.) An indefinite quantity contract is proposed. The quantities indicated are annual estimates only. The guaranteed minimum will be 75% of the annual estimate, and the contract maximum will be established at 150% of the annual estimate. The contract will have a base year with an option to extend the contract for an additional annual period. Contractor shall deliver to various locations, provided at time of award.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS